DK0495896T3 - Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel - Google Patents

Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel

Info

Publication number
DK0495896T3
DK0495896T3 DK90915992.3T DK90915992T DK0495896T3 DK 0495896 T3 DK0495896 T3 DK 0495896T3 DK 90915992 T DK90915992 T DK 90915992T DK 0495896 T3 DK0495896 T3 DK 0495896T3
Authority
DK
Denmark
Prior art keywords
hiv
infections
protection against
vaccine
preparation
Prior art date
Application number
DK90915992.3T
Other languages
English (en)
Inventor
Ursula Dietrich
Michalina Adamski
Hagen Von Briesen
Herbert Kuehnel
Helga Ruebsamen-Waigmann
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0495896(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Application granted granted Critical
Publication of DK0495896T3 publication Critical patent/DK0495896T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK90915992.3T 1989-10-14 1990-10-12 Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel DK0495896T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Publications (1)

Publication Number Publication Date
DK0495896T3 true DK0495896T3 (da) 1994-10-10

Family

ID=6391493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90915992.3T DK0495896T3 (da) 1989-10-14 1990-10-12 Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel

Country Status (8)

Country Link
US (1) US5861243A (da)
EP (1) EP0495896B1 (da)
JP (1) JP3152433B2 (da)
AT (1) ATE106748T1 (da)
DE (2) DE3934366A1 (da)
DK (1) DK0495896T3 (da)
ES (1) ES2055922T3 (da)
WO (1) WO1991005567A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
AU715731B2 (en) * 1994-10-20 2000-02-10 Institut Pasteur Nucleotide sequences of HIV-1 group (or subtype) O retrovirus antigens
US6124262A (en) * 1995-03-17 2000-09-26 The Regents Of The University Of California Compositions and methods for reducing adhesiveness of defective red blood cells
US6426412B1 (en) * 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
US7144699B2 (en) * 1997-03-20 2006-12-05 Affymetrix, Inc. Iterative resequencing
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
ATE516046T1 (de) 1999-05-13 2011-07-15 Wyeth Corp Adjuvans kombinationsformulierungen
DE60043856D1 (de) * 1999-12-23 2010-04-01 Medical Res Council Verbesserungen in oder in bezug auf immunantworten gegen hiv
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
SK5482003A3 (en) * 2000-11-10 2004-03-02 Wyeth Corp Adjuvant combination formulations
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
JP2008535783A (ja) 2005-02-15 2008-09-04 サイモン・エル・エル・シー Ｈｉｖ−１の増殖を弱めるための方法および組成物
US20100275278A1 (en) * 2006-02-03 2010-10-28 Karp Nelson M Animal model for hiv induced disease
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN115124628B (zh) * 2021-03-27 2023-03-31 中国科学院昆明植物研究所 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608294B2 (en) * 1987-01-16 1991-03-28 Institut Pasteur Peptides having immunological properties 2-hiv-2
ATE141946T1 (de) * 1988-06-14 1996-09-15 Qiagen Gmbh Hiv-2-virusvarianten

Also Published As

Publication number Publication date
JPH05505389A (ja) 1993-08-12
EP0495896B1 (de) 1994-06-08
DE3934366C2 (da) 1991-11-07
ATE106748T1 (de) 1994-06-15
DE59006080D1 (de) 1994-07-14
WO1991005567A1 (de) 1991-05-02
ES2055922T3 (es) 1994-09-01
US5861243A (en) 1999-01-19
DE3934366A1 (de) 1991-04-18
EP0495896A1 (de) 1992-07-29
JP3152433B2 (ja) 2001-04-03

Similar Documents

Publication Publication Date Title
DK0495896T3 (da) Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
ATE135747T1 (de) Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
DE69630457D1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
ES2054657T3 (es) Nuevos oligosacaridos y su metodo de preparacion.
HUP0302965A2 (hu) Vakcina
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
GR3022248T3 (en) Oligonucleotide sequences for amplification of type HIV-2 and SIV retroviruses genomes and their application to in-vitro diagnostic of infections caused by these viruses
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
ES426215A1 (es) Procedimiento para preparar una vacuna de adenovirus bovi- nos vivos.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
NO890565D0 (no) Forhindring og behandling av retroviral sykdom.
DK612889A (da) Enzym og fremgangsmaade til fremstilling deraf
CA2350127A1 (en) Avipox vector coding an hiv antigen and a cytokine
ATE143373T1 (de) Proteine, vakzine und nucleinsäuren
TH6220EX (th) ไวรัสแอนทิเจนวิธีการเตรียมและการใช้ในการวินิจฉัยและในการรักษา(วัคซีน)
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
TH6220A (th) ไวรัสแอนทิเจนวิธีการเตรียมและการใช้ในการวินิจฉัยและในการรักษา(วัคซีน)
FI945110A (fi) Tippuribakteerien rokotteiden valmistusmenetelmä
TH9629EX (th) โพรเทเอส, รีเวอร์ส แทรนส์คริพเทส และเอนโดนิวคลี เอสของ ของเรโทรไวรัส และวิธีการสำหรับผลิตเอนไซม์เหล่า นี้
TH23870EX (th) วัคซีนและวิธีสำหรับการเตรียม
TH23870A (th) วัคซีนและวิธีสำหรับการเตรียม